IP Library Granted Patent US 8,907,063
Granted Patent B2
US 8,907,063 · App. 13/776,559 · Granted Dec 9, 2014

TNF superfamily collectin fusion proteins and encoding nucleic acids

Inventors: Oliver Hill (Neckarsteinach, DE); Christian Gieffers (Dossenheim, DE); Meinolf Thiemann (Schriesheim, DE); Marcus Branschädel (Heidelberg, DE)
Assignee: Apogenix GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,907,063
App. No.
13/776,559
Granted
Dec 9, 2014
Kind
B2
Abstract

The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.

Claims (22)

1. A fusion protein comprising:

(i) a TNF (tumor necrosis factor)-superfamily cytokine of CD95L, or a receptor binding domain thereof, and

(ii) a collectin trimerization domain comprising a neck domain or a neck and carbohydrate binding domain of surfactant protein-D, wherein (ii) is located C-terminally of (i).

2. The fusion protein of claim 1 , further comprising a flexible linker between (i) and (ii), wherein the flexible linker is a glycine/serine linker and has a length of 3-20 amino acids.

3. The fusion protein of claim 2 , wherein the flexible linker has the amino acid sequence of SEQ ID NO: 53, which is (GSS) a (SSG) b (GSG) c wherein a, b, c is each 0, 1, 2, 3, 4, 5 or 6.

4. The fusion protein of claim 2 , wherein the flexible linker has a length of 9-15 amino acids.

5. The fusion protein of claim 2 , wherein the flexible linker has the amino acid sequence of SEQ ID NO: 54.

6. The fusion protein of claim 1 , wherein the CD95L has the amino acid sequence of SEQ ID NO: 6.

7. The fusion protein of claim 1 , wherein (i) comprises amino acids 142-281 or 144-281 of SEQ ID NO: 6.

8. The fusion protein of claim 1 , wherein (ii) comprises amino acids 217-375, 218-375, 219-375, 220-375, 221-375, 222-375, 223-375, 224-375, or 225-375 of human surfactant protein-D of SEQ ID NO:21.

9. The fusion protein of claim 1 , wherein (ii) comprises amino acids 217-257, 218-257, 219-257, 220-257, 221-257, 222-257, 223-257, 224-257, or 225-257 of human surfactant protein-D of SEQ ID NO:21.

10. The fusion protein of claim 1 , wherein (ii) comprises a mutant of SEQ ID NO:21 having only one amino acid substitution.

11. The fusion protein of claim 10 , wherein the amino acid substitution is at the amino acid position F355 of human surfactant protein-D of SEQ ID NO:21, and wherein the amino acid substitution is one of the following: F355A, F355S, F355T, F355E, F355D, F355K, or F355R.

12. The fusion protein of claim 1 , which comprises the sequence of SEQ ID NO: 40.

13. The fusion protein of claim 1 , which comprises amino acid residues 21-327 of SEQ ID NO: 40.

14. The fusion protein of claim 1 , which additionally comprises an N-terminal signal peptide domain.

15. The fusion protein of claim 14 , wherein the N-terminal signal peptide domain has the sequence SEQ ID NO:23, SEQ ID NO:24, or SEQ ID NO:25.

16. The fusion protein of claim 1 , wherein the fusion protein further comprises a recognition/purification domain located at the N-terminus or at the C-terminus.

17. The fusion protein of claim 16 , wherein the recognition/purification domain is a Strep-tag or a poly His-domain.

18. A trimeric complex formed by covalent linkages between three of the fusion proteins of claim 1 .

19. A nucleic acid molecule encoding the fusion protein of claim 1 .

20. A vector comprising the nucleic acid molecule of claim 18 .

Assignments (1)
CHANGE OF NAME Recorded Mar 21, 2016
From: APOGENIX GMBH
To: APOGENIX AG
Reel/Frame 038190/0226 →
Priority Claims (1)
EP 07013506 · Jul 10, 2007 · regional
Continuity (2)
Division 12668188
Related Publication 20130178604A1 · Jul 11, 2013